12 slides from Chanticleer's corporate update, Nov 2, 2022
Slide 1: Powering a New Wave of Immune Therapeutics
POWERING A NEW WAVE OF IMMUNE THERAPEUTICS SON-1010 Clinical Update Presentation November 2, 2022
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS, This presentation contains forward-looking statements about Sonnet. BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “
Slide 3: Sonnet Pipeline Targets: Multiple Points of Intervention
Sonnet Pipeline Targets Multiple Points of Intervention IL-18 Tumor Antigen news —— e isee ‘\ Lymph | Tumor r Mature Dendritic Fragments el Ce Feoteg autigen Effedtor cells: z ceptors 1. Activate other immune cells 2. Kill “target cells” Activated T-cell Mefnory collet” " Immature 1. Circulate month
Slide 4: Sonnet's Technology Advantage
Sonnet’s Technology Advantage Flexible Linkers THERAPEUTIC PAYLOAD B IL-12 ‘THERAPEUTIC PAYLOAD A BINDS TO SERUM ALBUMIN 8 oys-34 Z wwe ix F,AB-Albumin ¢ binds FcRn for enhanced pK and TME accumulation ia ne F,AB-Albumin complex binds to GP6O and ‘SPARC in the tumor microenvironment For a video disp
Slide 5: FAB: Accumulation in the Tumor Microenvironment
8 BioThe N NEI erapeutics FAB: Accumulation in the Tumor Microenvironment » 02 a 1 mor stood Vessel vest |} B Albuminiselevated in sod 1. IL-F,AB binds Endothelial rare Albumin in the blood (0) 8 a Celis ie FeRn over expressed in 2. IL-F,,AB — Albumin tumors binds to FeRn resulting in transport from
Slide 6: SON-1010: Reduces Tumor Volume
SON-1010: Reduces Tumor Volume IL12-F,yAB (1.3yg) vs IL-12 (30pg) in BL6F10 Melanoma Tumor Volume mm? ~~ Placebo AB IL12-FHAB (1.31g) = molar 0.99 of 1L-12 te IL-12 (30ng) 2857 1500 1:30 ratio of IL-12 1000 Days ‘Single dose when tumor was 100 mm? ; 8 mice/group IL-12 (1yg) and IL12- F,AB (1.39) are
Slide 7: Clinical Program: SB101/SB102 Study Designs
Clinical Program: SB101/SB102 Study Designs $B102: SAD for = Rapid enrollment of healthy volunteers in the SAD provides clean PK data without PKIPD/FACS in interpretation challenges from prior cancer Healthy Volunteers Loon eve ] treatment effects peserene * Simulation using continual reassessment =
Slide 8: SB101: Safety Data (unaudited, as of 10/31/22)
SB101: Safety Data (unaudited, as of 10/31/22) Related TEAEs by Grade 0.05 ug/kg (N=3), n (%) 0.15 ug/kg (N=3), n (%) 0.15 > 0.3 ualkg (N=3), n (%) Tachycardia (Grade 1) 1(33.3) Nausea (Grade 1) 183.3) Chills (Grade 1) 1(33.3) Fatigue (Grade 1) 1(33.3) Injection site pain (Grade 1) 1(33.3) 3 (100.0)
Slide 9: SB101: PK and Cytokine Responses
SB101: PK and Cytokine Responses Acute inflammation was assessed with a Luminex bead assay for multiple analytes in both studies IL-12p70 (used to measure SON-1010 concentration) was readily quantitated and shows extended pharmacokinetics Increase in IFNy (showing an IL-12 effect and potential for t
Slide 11: SB101 Clinical Program: High Level Summary
SB101 Clinical Program: High Level Summary » Allometric PK modeling suggests ty, in humans is 52 hrs Q Compares favorably with rhIL-12 ty, of 5-12 hrs ci! ] a Early SON-1010 data is consistent with the PK model No Dose Limiting Toxicities to date in 12 patients Mostly mild with very few Grade 2/3 AE